Literature DB >> 8428204

Selective IK blockade as an antiarrhythmic mechanism: effects of UK66,914 on ischaemia and reperfusion arrhythmias in rat and rabbit hearts.

S A Rees1, M J Curtis.   

Abstract

1. UK66,914 is a specific and selective blocker of the delayed rectifying potassium current (IK). The effectiveness of IK block as a mechanism for prevention of ischaemia- and reperfusion-induced arrhythmias was tested by use of UK66,914: its actions in rat, a species deficient in cardiac IK were compared with its actions in rabbit, a species possessing functional cardiac IK. Antiarrhythmic actions in rabbit but none in rat is the only outcome possible if selective IK blockade is responsible for the antiarrhythmic actions of the drug during ischaemia and/or reperfusion. 2. During 30 min regional ischaemia, 0.3 and 1 microM UK66,914 had no influence on the incidence of ventricular fibrillation (VF) in rat (n = 9/group), values being 78% in controls, 100% in 0.3 microM-treated hearts and 78% in 1.0 microM-treated hearts (NS). UK66,914 also had no effect on reperfusion-induced VF incidence (100% in each group), nor on the latency to onset of ischaemia- or reperfusion-induced arrhythmias. In contrast, in rabbit (n = 13/group), similar concentrations of drug reduced the incidence of reperfusion-induced VF from 77% in controls, to 38% and 31% (P < 0.05) respectively. The incidence of ischaemia-induced arrhythmias was too low in controls to permit detection of an antiarrhythmic effect in rabbit; however no drug-induced proarrhythmia was seen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428204      PMCID: PMC1907696          DOI: 10.1111/j.1476-5381.1993.tb13453.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  The Sicilian Gambit and antiarrhythmic drug development.

Authors:  T J Colatsky
Journal:  Cardiovasc Res       Date:  1992-06       Impact factor: 10.787

2.  Species differences in susceptibility to ischemic injury and responsiveness to myocardial protection.

Authors:  M Galiñanes; D J Hearse
Journal:  Cardioscience       Date:  1990-06

3.  Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade?

Authors:  K Tsuchihashi; M J Curtis
Journal:  J Cardiovasc Pharmacol       Date:  1991-09       Impact factor: 3.105

4.  Acute phase of myocardial infarction.

Authors:  A A Adgey; J D Allen; J S Geddes; R G James; S W Webb; S A Zaidi; J F Pantridge
Journal:  Lancet       Date:  1971-09-04       Impact factor: 79.321

5.  [Ventricular tachycardia with 2 variable opposing foci].

Authors:  F Dessertenne
Journal:  Arch Mal Coeur Vaiss       Date:  1966-02

6.  Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study.

Authors:  R W Campbell; A Murray; D G Julian
Journal:  Br Heart J       Date:  1981-10

7.  Myocardial extracellular K+ and H+ increase and noradrenaline release as possible cause of early arrhythmias following acute coronary artery occlusion in pigs.

Authors:  H Hirche; C Franz; L Bös; R Bissig; R Lang; M Schramm
Journal:  J Mol Cell Cardiol       Date:  1980-06       Impact factor: 5.000

8.  Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent.

Authors:  M Gwilt; H W Dalrymple; R A Burges; K J Blackburn; R P Dickinson; P E Cross; A J Higgins
Journal:  J Cardiovasc Pharmacol       Date:  1991-03       Impact factor: 3.105

9.  The rabbit dual coronary perfusion model: a new method for assessing the pathological relevance of individual products of the ischaemic milieu: role of potassium in arrhythmogenesis.

Authors:  M J Curtis
Journal:  Cardiovasc Res       Date:  1991-12       Impact factor: 10.787

10.  Assessment of emetine cardiotoxicity in a subacute toxicity experiment in rats.

Authors:  G Zbinden; R Kleinert; B Rageth
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

View more
  8 in total

1.  Greater antiarrhythmic activity of acute 17beta-estradiol in female than male anaesthetized rats: correlation with Ca2+ channel blockade.

Authors:  K L Philp; M Hussain; N F Byrne; M J Diver; G Hart; S J Coker
Journal:  Br J Pharmacol       Date:  2006-08-29       Impact factor: 8.739

2.  Antiarrhythmic drug research.

Authors:  M J A Walker
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

4.  Mechanism of 5-hydroxytryptamine-induced coronary vasodilation assessed by direct detection of nitric oxide production in guinea-pig isolated heart.

Authors:  A J Ellwood; M J Curtis
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

5.  IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats.

Authors:  J Chen; S Komori; B Li; K Tamura; K Hashimoto
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

6.  Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism.

Authors:  Kathryn E Baker; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

7.  Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

Authors:  D R Blue; D W Bonhaus; A P Ford; J R Pfister; N A Sharif; I A Shieh; R L Vimont; T J Williams; D E Clarke
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

Review 8.  Acute Stress Decreases but Chronic Stress Increases Myocardial Sensitivity to Ischemic Injury in Rodents.

Authors:  Eric D Eisenmann; Boyd R Rorabaugh; Phillip R Zoladz
Journal:  Front Psychiatry       Date:  2016-04-25       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.